Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Massachusetts General Hospital stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Topics

Neurodegenerative diseaseAlzheimer’s & dementiaAlzheimer's diseaseBiotech innovationVenture capital fundingDrug developmentDrug discoveryBiotech startupEli Lilly

Related entities

LondonParkinson's disease